Indonesia childhood vaccine schedule: 9 vaccines by age
For babies (first year): BCG (tuberculosis), Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR. Click a vaccine for its Indonesia-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| BCG (tuberculosis) · side effects & data | Universal | Dose 1 — 0-1 month |
| Hepatitis B · side effects & data | Universal | Dose 1 — At birth (HB-0 then pentavalent) Dose 2 — 2 months (HB-0 then pentavalent) Dose 3 — 3 months (HB-0 then pentavalent) Dose 4 — 4 months (HB-0 then pentavalent) |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 2 months (Pentavalent then DPT) Dose 2 — 3 months (Pentavalent then DPT) Dose 3 — 4 months (Pentavalent then DPT) Booster — 18 months (Pentavalent then DPT) |
| Polio (IPV) · side effects & data | Universal | Dose 0 — At birth (OPV and IPV) Dose 1 — 2 months (OPV and IPV) Dose 2 — 3 months (OPV and IPV) Dose 3 — 4 months (OPV and IPV) IPV dose — 4 months (OPV and IPV) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 3 months Dose 3 — 4 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 3 months Dose 3 — 4 months |
| Rotavirus · side effects & data | Universal | Dose 1 — 2 months (Rotavirus (oral)) Dose 2 — 3 months (Rotavirus (oral)) Dose 3 — 4 months (Rotavirus (oral)) |
| MMR · side effects & data | Universal | Dose 1 — 9 months (MR / MMR) Dose 2 — 18 months (MR / MMR) |
| HPV · side effects & data | Selective / risk-based | Dose 1 — 11-12 years Dose 2 — 6-12 months after dose 1 |
Indonesia vaccine schedule vs. the United States
Indonesia and the United States share 8 routine vaccines. Indonesia also routinely gives BCG (tuberculosis), which the U.S. does not. The U.S. routinely gives Varicella (chickenpox), Hepatitis A, Meningococcal, Influenza (flu), COVID-19, which Indonesia does not.
| Vaccine | Indonesia first dose | U.S. first dose | Doses |
|---|---|---|---|
| Hepatitis B | At birth | Birth | 4 vs 3 doses |
| DTaP / Tdap | 2 months | 2 months | 4 vs 5 doses |
| Polio (IPV) | At birth | 2 months | 5 vs 4 doses |
| Hib | 2 months | 2 months | 3 vs 4 doses |
| Pneumococcal (PCV) | 2 months | 2 months | 3 vs 4 doses |
| Rotavirus | 2 months | 2 months | 3 vs 3 doses |
| MMR | 9 months | 12-15 months | 2 vs 2 doses |
| HPV | 11-12 years | 11-12 years | 2 vs 2 doses |
In the Indonesia schedule but not the routine U.S. schedule: BCG (tuberculosis).
In the routine U.S. schedule but not Indonesia's: Varicella (chickenpox), Hepatitis A, Meningococcal, Influenza (flu), COVID-19.
Why Indonesia's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 382 new cases per 100,000 people per year (2024) — about 119× the U.S. rate. BCG is given to every newborn nationwide. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 128.1 reported cases per million people (2025). Two-dose coverage is 78%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: 72% coverage. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | Indonesia | United States |
|---|---|---|
| BCG (TB) | 85% (2025) | not reported |
| DTP dose 1 | 85% (2025) | 98% (2025) |
| DTP dose 3 | 82% (2025) | 94% (2025) |
| Measles dose 1 | 85% (2025) | 92% (2025) |
| Measles dose 2 | 78% (2025) | 95% (2025) |
| Polio (IPV series) | 76% (2025) | 93% (2025) |
| Hep B birth dose | 72% (2025) | 75% (2025) |
| Hep B dose 3 | 82% (2025) | 93% (2025) |
| Hib dose 3 | 82% (2025) | 92% (2025) |
| Pneumococcal (PCV) | 69% (2025) | 84% (2025) |
| Rotavirus (complete) | 71% (2025) | 77% (2025) |
| HPV dose 1, girls | 83% (2025) | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).
Other Asia-Pacific countries
Australia · Japan · Philippines · South Korea · Vietnam · all 31 countries